$SLNO
SOLENO THERAPEUTICS INC Stock $slno

$slno Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024027500 Filed on March 07, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$8.472M	$4.140M	$13.48M
YoY Change	196.85%	72.36%	36.95%
% of Gross Profit
Research & Development	$14.60M	$8.689M	$25.19M
YoY Change	174.68%	128.06%	65.01%
% of Gross Profit
Depreciation & Amortization	$490.0K	$489.0K	$1.958M
YoY Change	0.0%	0.2%	9690.0%
% of Gross Profit
Operating Expenses	$23.48M	$13.91M	$41.38M
YoY Change	177.19%	147.95%	69.63%
Operating Profit	-$23.48M		-$41.38M
YoY Change	177.19%		69.63%
Interest Expense	$2.077M	$2.144M	$2.578M
YoY Change	1738.05%	1615.2%	759.33%
% of Operating Profit
Other Income/Expense, Net	$2.077M	$470.0K	-$182.0K
YoY Change	1738.05%	-47100.0%	-155.15%
Pretax Income	-$21.40M	-$11.30M	-$38.99M
YoY Change	156.08%	105.91%	62.0%
Income Tax
% Of Pretax Income
Net Earnings	-$21.40M	-$11.30M	-$38.99M
YoY Change	154.76%	105.91%	61.78%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.59		-$2.36
Diluted Earnings Per Share	-$0.59	-$0.33	-$2.36
COMMON SHARES
Basic Shares Outstanding	32.46M	30.50M	16.49M
Diluted Shares Outstanding	36.21M		16.49M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$149.6M	$169.7M	$169.7M
YoY Change	1800.27%	1062.04%	1062.04%
Cash & Equivalents	$42.80M	$169.7M	$169.7M
Short-Term Investments	$106.8M
Other Short-Term Assets	$1.596M	$1.677M	$1.677M
YoY Change	27.37%	60.48%	60.48%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$151.2M	$171.4M	$171.4M
YoY Change	1556.88%	995.15%	995.15%
LONG-TERM ASSETS
Property, Plant & Equipment	$27.00K	$419.0K	$419.0K
YoY Change	22.73%	1511.54%	166.88%
Goodwill
YoY Change
Intangibles	$8.263M	$8.749M
YoY Change	-19.05%	-18.18%
Long-Term Investments	$8.821M
YoY Change
Other Assets	$165.0K	$165.0K	$165.0K
YoY Change	30.95%
Total Long-Term Assets	$17.61M	$9.333M	$9.333M
YoY Change	69.24%	-13.98%	-13.98%
TOTAL ASSETS
Total Short-Term Assets	$151.2M	$171.4M	$171.4M
Total Long-Term Assets	$17.61M	$9.333M	$9.333M
Total Assets	$168.8M	$180.7M	$180.7M
YoY Change	764.28%	581.93%	581.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.022M	$3.149M	$3.149M
YoY Change	188.77%	77.21%	77.21%
Accrued Expenses	$3.931M	$6.801M	$6.801M
YoY Change	-8.39%	34.62%	34.62%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$13.46M	$11.51M	$11.51M
YoY Change	73.48%	57.32%	57.32%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$11.99M	$11.68M	$11.68M
YoY Change	31.22%	32.18%	32.18%
Total Long-Term Liabilities	$11.99M	$11.68M	$11.68M
YoY Change	31.22%	32.18%	32.18%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.46M	$11.51M	$11.51M
Total Long-Term Liabilities	$11.99M	$11.68M	$11.68M
Total Liabilities	$25.45M	$23.18M	$23.18M
YoY Change	50.63%	43.56%	43.56%
SHAREHOLDERS EQUITY
Retained Earnings	-$297.8M	-$276.4M
YoY Change	21.16%	16.43%
Common Stock	$441.3M	$433.9M
YoY Change	77.66%	75.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$143.4M	$157.5M	$157.5M
YoY Change
Total Liabilities & Shareholders Equity	$168.8M	$180.7M	$180.7M
YoY Change	764.28%	581.93%	581.93%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$21.40M	-$11.30M	-$38.99M
YoY Change	154.76%	105.91%	61.78%
Depreciation, Depletion And Amortization	$490.0K	$489.0K	$1.958M
YoY Change	0.0%	0.2%	9690.0%
Cash From Operating Activities	-$12.50M	-$6.314M	-$24.94M
YoY Change	86.57%	22.77%	19.9%
INVESTING ACTIVITIES
Capital Expenditures	$11.00K	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$115.2M
YoY Change
Cash From Investing Activities	-$115.2M	$0.00	$0.00
YoY Change		-100.0%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$180.0M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	938.0K	123.6M	180.0M
YoY Change			1177.46%
NET CHANGE
Cash From Operating Activities	-12.50M	-6.314M	-24.94M
Cash From Investing Activities	-115.2M	0.000	0.000
Cash From Financing Activities	938.0K	123.6M	180.0M
Net Change In Cash	-126.8M	117.2M	155.1M
YoY Change	1785.17%	-2377.02%	-2413.92%
FREE CASH FLOW
Cash From Operating Activities	-$12.50M	-$6.314M	-$24.94M
Capital Expenditures	$11.00K	$0.00	$0.00
Free Cash Flow	-$12.51M	-$6.314M	-$24.94M
YoY Change	86.73%	22.63%	19.83%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001484565
CY2023	dei	Entity Registrant Name EntityRegistrantName	SOLENO THERAPEUTICS INC
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2022Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0666
CY2022Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0666
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityCurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityCurrent
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityNoncurrent
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityNoncurrent
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-36593
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0523891
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	203 Redwood Shores Parkway
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 500
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Redwood City
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94065
CY2023	dei	City Area Code CityAreaCode	650
CY2023	dei	Local Phone Number LocalPhoneNumber	213-8444
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2023	dei	Trading Symbol TradingSymbol	SLNO
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	33100000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	32460579
CY2023	dei	Auditor Name AuditorName	Marcum LLP
CY2023	dei	Auditor Location AuditorLocation	San Francisco, CA
CY2023	dei	Auditor Firm AuditorFirmId	688
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	169681000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14602000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1677000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1045000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	171358000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	15647000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	26000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	407000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	131000
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	8749000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	10693000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	165000
CY2023Q4	us-gaap	Assets Assets	180691000
CY2022Q4	us-gaap	Assets Assets	26497000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3149000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1777000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3135000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1675000
CY2023Q4	slno	Accrued Clinical Trial Costs Current AccruedClinicalTrialCostsCurrent	3393000
CY2022Q4	slno	Accrued Clinical Trial Costs Current AccruedClinicalTrialCostsCurrent	3222000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	273000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	155000
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1555000
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	484000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11505000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7313000
CY2023Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent	11549000
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent	8835000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	130000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0
CY2023Q4	us-gaap	Liabilities Liabilities	23184000
CY2022Q4	us-gaap	Liabilities Liabilities	16149000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31678159
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31678159
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8159382
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8159382
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	32000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	8000
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	433885000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	247762000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-276410000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-237422000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	157507000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	10348000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	180691000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	26497000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25189000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15265000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13481000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9844000
CY2023	slno	Asset Acquisition Contingent Consideration Change In Fair Value AssetAcquisitionContingentConsiderationChangeInFairValue	2714000
CY2022	slno	Asset Acquisition Contingent Consideration Change In Fair Value AssetAcquisitionContingentConsiderationChangeInFairValue	-712000
CY2023	us-gaap	Operating Expenses OperatingExpenses	41384000
CY2022	us-gaap	Operating Expenses OperatingExpenses	24397000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-41384000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-24397000
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	182000
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-30000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2578000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	300000
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2396000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	330000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-38988000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-24067000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.36
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24940000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20781000
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.36
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.87
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.87
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16492132
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16492132
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8397088
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8397088
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	17793000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2530000
CY2022	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	16000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	4439000
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	342000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-24067000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	10348000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5809000
CY2023	slno	Issuance Of Restricted Stock Units Value Under Equity Incentive Plan IssuanceOfRestrictedStockUnitsValueUnderEquityIncentivePlan	136000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	8449000
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	137857000
CY2023	slno	Exercise Of Common Stock Warrants ExerciseOfCommonStockWarrants	41998000
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	-347000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-38988000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	157507000
CY2023	us-gaap	Profit Loss ProfitLoss	-38988000
CY2022	us-gaap	Profit Loss ProfitLoss	-24067000
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1958000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1964000
CY2023	slno	Noncash Lease Expense NoncashLeaseExpense	321000
CY2022	slno	Noncash Lease Expense NoncashLeaseExpense	290000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	5945000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2530000
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	182000
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-30000
CY2023	slno	Asset Acquisition Contingent Consideration Change In Fair Value AssetAcquisitionContingentConsiderationChangeInFairValue	2714000
CY2022	slno	Asset Acquisition Contingent Consideration Change In Fair Value AssetAcquisitionContingentConsiderationChangeInFairValue	-712000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	837000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-113000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1372000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1477000
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1460000
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	947000
CY2023	slno	Increase Decrease In Accrued Clinical Trial Site Costs IncreaseDecreaseInAccruedClinicalTrialSiteCosts	171000
CY2022	slno	Increase Decrease In Accrued Clinical Trial Site Costs IncreaseDecreaseInAccruedClinicalTrialSiteCosts	-198000
CY2023	slno	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-309000
CY2022	slno	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-302000
CY2023	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	1071000
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	161000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13000
CY2023	slno	Proceeds From Sale Of Common Stock Common Stock Warrants And Pre Funded Stock Warrants Net Of Issuance Costs ProceedsFromSaleOfCommonStockCommonStockWarrantsAndPreFundedStockWarrantsNetOfIssuanceCosts	137857000
CY2022	slno	Proceeds From Sale Of Common Stock Common Stock Warrants And Pre Funded Stock Warrants Net Of Issuance Costs ProceedsFromSaleOfCommonStockCommonStockWarrantsAndPreFundedStockWarrantsNetOfIssuanceCosts	14108000
CY2023	slno	Proceeds From Exercise Of Common Stock Warrants And Pre Funded Stock Warrants Net Of Costs ProceedsFromExerciseOfCommonStockWarrantsAndPreFundedStockWarrantsNetOfCosts	41815000
CY2022	slno	Proceeds From Exercise Of Common Stock Warrants And Pre Funded Stock Warrants Net Of Costs ProceedsFromExerciseOfCommonStockWarrantsAndPreFundedStockWarrantsNetOfCosts	0
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	347000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	16000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	180019000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14092000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	155079000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6702000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14602000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21304000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	169681000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14602000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	597000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0
CY2023	slno	Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Warrants Exercised NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsExercised	183000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-39000000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-276400000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	169700000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24900000
CY2023Q4	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	129000000
CY2022Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	one-for-fifteen
CY2022Q3	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	110000000
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of expenses in the financial statements and accompanying notes. Actual results could differ from those estimates. Key estimates in the financial statements include the valuation of deferred income tax assets, the valuation of financial instruments, stock-based compensation, accrued costs for services rendered in connection with third-party contractor clinical trial activities, and the valuation of contingent liabilities for the purchase price of assets obtained through acquisition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents at U.S. banking institutions. At December 31, 2023, the majority of the Company’s funds were invested with two separate financial institutions and at times these balances may exceed the federally-insured limits. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating cash in excess of federally-insured limits is custodied at a separate financial institution with an overnight sweep feature into a U.S. government money market fund. As of December 31, 2022, the Company’s funds were invested in one financial institution which at times may exceed the federally insured limit.</span></p>
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023Q4	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P11Y
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	89000
CY2023	slno	Milestones Payment MilestonesPayment	100000000
CY2022	slno	Milestones Payment MilestonesPayment	200000000
CY2023	slno	Percentage Of Probability Of Achieving Milestone PercentageOfProbabilityOfAchievingMilestone	0.88
CY2022	slno	Percentage Of Probability Of Achieving Milestone PercentageOfProbabilityOfAchievingMilestone	0.72
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	101000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	101000
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	312000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	324000
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	44000
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	29000
CY2023	slno	Operating Lease Cost And Sublease Income OperatingLeaseCostAndSubleaseIncome	356000
CY2022	slno	Operating Lease Cost And Sublease Income OperatingLeaseCostAndSubleaseIncome	353000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	75000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	26000
CY2023	us-gaap	Depreciation Depreciation	14000
CY2022	us-gaap	Depreciation Depreciation	20000
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	1900000
CY2023	us-gaap	Adjustment For Amortization AdjustmentForAmortization	1900000
CY2023	slno	Lessee Operating Lease Extension Expiration Month And Year LesseeOperatingLeaseExtensionExpirationMonthAndYear	2025-05
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	300000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	200000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	100000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0
CY2023	slno	Operating Lease Right Of Use Asset Increase OperatingLeaseRightOfUseAssetIncrease	600000
CY2023	slno	Increase In Operating Lease Liability IncreaseInOperatingLeaseLiability	600000
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0825
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P17M
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.09
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5M
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	341000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	354000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	287000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	143000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	430000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	27000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	403000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	slno	Public Offering Price Per Pre Funded Warrant PublicOfferingPricePerPreFundedWarrant	19.99
CY2023	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	129000000
CY2023Q4	slno	Stock Issued Issuance Costs StockIssuedIssuanceCosts	8200000
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	13071883
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5323110
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5900000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2500000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5945000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2530000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.04
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.62
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-39180000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-24173000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	192000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	106000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-38988000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-24067000
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-8187000
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5055000
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-505000
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-527000
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	6000
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	8934000
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	5702000
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1631000
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	652000
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-600000
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-734000
CY2023	slno	Income Tax Reconciliation Change In Fair Value Of Warrants IncomeTaxReconciliationChangeInFairValueOfWarrants	38000
CY2022	slno	Income Tax Reconciliation Change In Fair Value Of Warrants IncomeTaxReconciliationChangeInFairValueOfWarrants	-6000
CY2023	slno	Income Tax Reconciliation Change In Fair Value Of Contingent Consideration IncomeTaxReconciliationChangeInFairValueOfContingentConsideration	570000
CY2022	slno	Income Tax Reconciliation Change In Fair Value Of Contingent Consideration IncomeTaxReconciliationChangeInFairValueOfContingentConsideration	-150000
CY2023	slno	Income Tax Reconciliation Section One Sixty Two Limitation IncomeTaxReconciliationSectionOneSixtyTwoLimitation	589000
CY2023	slno	Income Tax Reconciliation Change In Net Operating Loss IncomeTaxReconciliationChangeInNetOperatingLoss	-39000
CY2022	slno	Income Tax Reconciliation Change In Net Operating Loss IncomeTaxReconciliationChangeInNetOperatingLoss	-739000
CY2022	slno	Income Tax Reconciliation Change In Capital Losses IncomeTaxReconciliationChangeInCapitalLosses	405000
CY2023	slno	Income Tax Reconciliation Change In State Rates IncomeTaxReconciliationChangeInStateRates	653000
CY2022	slno	Income Tax Reconciliation Change In State Rates IncomeTaxReconciliationChangeInStateRates	375000
CY2023	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	94000
CY2022	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-97000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	51481000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	49024000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	6352000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	4146000
CY2023Q4	slno	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	6778000
CY2022Q4	slno	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	2828000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	655000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	547000
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	29000
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	44000
CY2023Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	432000
CY2022Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	555000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2013000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2682000
CY2023Q4	slno	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	85000
CY2022Q4	slno	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	42000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	54000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	72000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	67879000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	59940000
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	1837000
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	2888000
CY2023Q4	slno	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	86000
CY2022Q4	slno	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	35000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1923000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2923000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	65956000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	57017000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	65956000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	57017000
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	8900000
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1936000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1557000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1002000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	379000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2938000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1936000
CY2023Q4	slno	Unrecognized Assets And Liabilities Related To Uncertain Tax Positions UnrecognizedAssetsAndLiabilitiesRelatedToUncertainTaxPositions	2900000
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0
CY2023Q4	slno	Unrecognized Tax Benefits Offset By Valuation Allowance UnrecognizedTaxBenefitsOffsetByValuationAllowance	2900000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16492132
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16492132
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8397088
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8397088
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11072169
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4747787
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	0

Files In Submission

Name	View Source	Status
0000950170-24-027500-index-headers.html	Edgar Link	pending
0000950170-24-027500-index.html	Edgar Link	pending
0000950170-24-027500.txt	Edgar Link	pending
0000950170-24-027500-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img175354480_0.jpg	Edgar Link	pending
img175354480_1.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
slno-20231231.htm	Edgar Link	pending
slno-20231231.xsd	Edgar Link	pending
slno-ex10_58.htm	Edgar Link	pending
slno-ex10_59.htm	Edgar Link	pending
slno-ex21_1.htm	Edgar Link	pending
slno-ex23_1.htm	Edgar Link	pending
slno-ex31_1.htm	Edgar Link	pending
slno-ex31_2.htm	Edgar Link	pending
slno-ex32_1.htm	Edgar Link	pending
slno-ex32_2.htm	Edgar Link	pending
slno-ex97_1.htm	Edgar Link	pending
slno-20231231_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SLNO
SOLENO THERAPEUTICS INC Stock $slno

2024 Q1 Form 10-K Financial Statement

#000095017024027500 Filed on March 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLNO SOLENO THERAPEUTICS INC Stock $slno

2024 Q1 Form 10-K Financial Statement

#000095017024027500 Filed on March 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLNO
SOLENO THERAPEUTICS INC Stock $slno